---
document_datetime: 2025-05-23 15:14:19
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jemperli-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: jemperli-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.5325701
conversion_datetime: 2025-12-28 03:51:33.437932
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## JEMPERLI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                            |
|----------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------|
| II/0040              | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/04/2025                          |                                             | SmPC and PL                      |                                                                    |
| II/0032              | Extension of indication for JEMPERLI to include, in combination with carboplatin and paclitaxel, the first-       | 12/12/2024                          | 15/01/2025                                  | SmPC, Annex II and PL            | Please refer to Scientific Discussion 'Jemperli-H-C-5205-II- 0032' |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy based on Interim Analysis 1 and 2 from study RUBY Part 1 (213361). This is a phase 3, randomized, double- blind, controlled study evaluating the efficacy and safety of dostarlimab plus carboplatin and paclitaxel in primary advanced or recurrent EC versus placebo plus carboplatin and paclitaxel. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Annex II.D and Package Leaflet are updated in accordance. Version 4.2 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the SmPC and to align the PI with the latest QRD template version 10.4. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |          |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| PSUSA/10931 /202404 | Periodic Safety Update EU Single assessment - dostarlimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28/11/2024 | n/a        |          | PRAC Recommendation - maintenance |
| II/0038/G           | This was an application for a group of variations. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21/11/2024 | 15/01/2025 | Annex II |                                   |

<div style=\"page-break-after: always\"></div>

|           | MCB and/or WCB B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product   |            |            |             | storage site of   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------|
| IA/0039   | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/10/2024 | n/a        |             |                   |
| IA/0036/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/08/2024 | n/a        |             |                   |
| IAIN/0037 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 30/07/2024 | 15/01/2025 | SmPC and PL |                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0035           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/07/2024   | 15/01/2025   | SmPC and PL           |                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|--------------------------------------------------------------------|
| IB/0033             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                            | 16/07/2024   | n/a          |                       |                                                                    |
| II/0031             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 30/05/2024   | 15/01/2025   | SmPC, Annex II and PL |                                                                    |
| PSUSA/10931 /202310 | Periodic Safety Update EU Single assessment - dostarlimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/05/2024   | n/a          |                       | PRAC Recommendation - maintenance                                  |
| IB/0029             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                               | 08/01/2024   | n/a          |                       |                                                                    |
| II/0023             | Extension of indication to include in combination with carboplatin and paclitaxel the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy, based on results from study 213361 (RUBY) Part 1, listed as a Specific Obligation in the Annex II; this is a phase 3, randomized, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients | 12/10/2023   | 07/12/2023   | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Jemperli-H-C-5204-II- 0023' |

<div style=\"page-break-after: always\"></div>

|                     | cancer. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 3.2 of the RMP has also been submitted. This submission fulfils SOB002 thus supporting the switch from CMA to full MA. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10931 /202304 | Periodic Safety Update EU Single assessment - dostarlimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/11/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0028             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 28/11/2023 | n/a |                                   |
| IAIN/0027           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/10/2023 | n/a |                                   |
| IB/0025             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/08/2023 | n/a |                                   |
| PSUSA/10931 /202210 | Periodic Safety Update EU Single assessment - dostarlimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/05/2023 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0022   | B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                              | 28/03/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0017    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                             | 15/12/2022   | 15/02/2023 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional marketing authorisation for JEMPERLI, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0021/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 01/02/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0020/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 01/02/2023   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0019/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                          | 01/02/2023   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013             | Update of section 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study 4010-01-001 (GARNET) listed as a specific obligation (SOB) in the Annex II; This is a single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumours. Update of Annex II to remove the specific obligation. In addition, the MAH took the opportunity to update Annex II in line with the QRD template version 10.3. The RMP version 2.1 is approved. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/12/2022   | 15/02/2023 | SmPC and Annex II | A total of 143 patients with dMMR/MSI H EC were evaluated for efficacy in the GARNET study. The overall median treatment duration in weeks was 34 (range 2 to 220). Twenty four percent of subjects who received any amount of dostarlimab received treatment >102 weeks (2 years). Dostarlimab treatment resulted in an Objective Response Rate (ORR) by response evaluation criteria in solid tumours (RECIST) v1.1 of 45.5% (95% CI: 37.1, 54.0) in patients with dMMR/MSI-H endometrial cancer. A complete response (CR) was reported in 23 (16.1%) dMMR/MSI-H patients. Median duration of response (DOR) was not reached at the time of data cutoff. The number of patients with duration of response ≥ 12 months and ≥ 24 months was 52 (80%) and 29 (44.6%) respectively. Disease control rate (DCR) was of 60.1% (n=86). For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10931 /202204 | Periodic Safety Update EU Single assessment - dostarlimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/12/2022   | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0016             | C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10/10/2022   | 15/02/2023 | Annex II          | To update Annex II in order to change the due date for the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             | efficacy study 'RUBY' from '31 December 2022' to '31 August 2023'.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007 | Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update dose modifications recommendations in immune related adverse reactions, amend existing warnings, and add further immune-related ADRs to the list of adverse drug reactions (ADRs), with different frequencies, based on data from company sponsored trials and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor changes to sections 4.6 and 5.2 of the SmPC and to update the list of local representatives in the Package Leaflet. Changes are also made to the PI to bring it in line with the current QRD template version and excipients guideline. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/07/2022 | 13/09/2022 | SmPC and PL | Recommended dose modifications have been added to section 4.2 of the SmPC for myocarditis and severe neurological toxicities (myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, encephalitis, transverse myelitis). Furthermore, the table of recommended dose modifications has been amended to reflect a more precise terminology 'Exfoliative dermatologic conditions (e.g. Stevens Johnson syndrom (SJS), toxic epidermal necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS))' for immune-related cutaneous adverse effects. Section 4.4 of the SmPC has been updated in accordance. Based on available safety data, the following ADRs have also been included in the SmPC, section 4.8: encephalitis, myasthenia gravis, myasthenic syndrome, myocarditis, gastritis (including gastritis, immune-mediated gastritis and vasculitis gastrointestinal), oesophagitis, immune-mediated arthritis, polymyalgia rheumatica, myositis and systemic inflammatory response syndrome. In addition, immune- mediated enterocolitis and enteritis have been included as part of the composite term 'colitis'. For more information, please refer to the Summary of Product Characteristics. |
| IB/0015 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 08/09/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IB/0012             | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/06/2022   | n/a        |                    |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------|-----------------------------------|
| PSUSA/10931 /202110 | Periodic Safety Update EU Single assessment - dostarlimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/06/2022   | n/a        |                    | PRAC Recommendation - maintenance |
| IB/0011/G           | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                         | 08/06/2022   | 13/09/2022 | SmPC and Labelling |                                   |
| II/0009             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/04/2022   | 13/09/2022 | SmPC and PL        |                                   |
| IA/0010/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 02/03/2022   | n/a        |                    |                                   |

<div style=\"page-break-after: always\"></div>

| R/0004    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/12/2021   | 16/02/2022   | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for JEMPERLI, subject to the Specific Obligations and Conditions as laid down in Annex II   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006   | B.II.e.z - Change in container closure system of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/11/2021   | n/a          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0005   | B.II.e.z - Change in container closure system of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/11/2021   | n/a          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0003/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.z - Administrative change - Other variation | 17/09/2021   | n/a          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | Change in container closure system of the Finished Product - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method   |            |            |             | B.II.e.z -   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------|
| IB/0002 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                            | 01/07/2021 | 16/02/2022 | SmPC and PL |              |
| IA/0001 | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                           | 20/05/2021 | n/a        |             |              |